For other tumor types such as esophageal carcinoma (ESCA), bladder urothelial carcinoma (BLCA) and uterine corpus endometrial carcinoma (UCEC), which had comparable rates of KLF5 amplification and deletion, KLF5 expression changed in accordance to its copy number (Figure 2, bottom 3). This evidence concerns the gene KLF5 and bladder transitional cell carcinoma.